These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 26467777)
1. Hepatic outcomes among adults taking duloxetine: a retrospective cohort study in a US health care claims database. Lin ND; Norman H; Regev A; Perahia DG; Li H; Chang CL; Dore DD BMC Gastroenterol; 2015 Oct; 15():134. PubMed ID: 26467777 [TBL] [Abstract][Full Text] [Related]
2. Serotonin-Norepinephrine Reuptake Inhibitors and the Risk of AKI: A Cohort Study of Eight Administrative Databases and Meta-Analysis. Renoux C; Lix LM; Patenaude V; Bresee LC; Paterson JM; Lafrance JP; Tamim H; Mahmud SM; Alsabbagh MW; Hemmelgarn B; Dormuth CR; Ernst P; Clin J Am Soc Nephrol; 2015 Oct; 10(10):1716-22. PubMed ID: 26231193 [TBL] [Abstract][Full Text] [Related]
3. Treatment with duloxetine in adults and the incidence of cardiovascular events. Xue F; Strombom I; Turnbull B; Zhu S; Seeger J J Clin Psychopharmacol; 2012 Feb; 32(1):23-30. PubMed ID: 22198454 [TBL] [Abstract][Full Text] [Related]
4. Duloxetine for depression and the incidence of hepatic events in adults. Xue F; Strombom I; Turnbull B; Zhu S; Seeger JD J Clin Psychopharmacol; 2011 Aug; 31(4):517-22. PubMed ID: 21694615 [TBL] [Abstract][Full Text] [Related]
5. Antidepressants and Hepatotoxicity: A Cohort Study among 5 Million Individuals Registered in the French National Health Insurance Database. Billioti de Gage S; Collin C; Le-Tri T; Pariente A; Bégaud B; Verdoux H; Dray-Spira R; Zureik M CNS Drugs; 2018 Jul; 32(7):673-684. PubMed ID: 29959758 [TBL] [Abstract][Full Text] [Related]
6. Hepatic effects of duloxetine-III: analysis of hepatic events using external data sources. Strombom I; Wernicke JF; Seeger J; D'Souza DN; Acharya N Curr Drug Saf; 2008 May; 3(2):154-62. PubMed ID: 18690993 [TBL] [Abstract][Full Text] [Related]
7. First-Trimester Pregnancy Exposure to Venlafaxine or Duloxetine and Risk of Major Congenital Malformations: A Systematic Review. Lassen D; Ennis ZN; Damkier P Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):32-6. PubMed ID: 26435496 [TBL] [Abstract][Full Text] [Related]
8. [Hyponatremia associated with SSRI/NRSI: Descriptive and comparative epidemiological study of the incidence rates of the notified cases from the data of the French National Pharmacovigilance Database and the French National Health Insurance]. Revol R; Rault C; Polard E; Bellet F; Guy C Encephale; 2018 Jun; 44(3):291-296. PubMed ID: 29248119 [TBL] [Abstract][Full Text] [Related]
9. Differential inhibition of cardiac and neuronal Na(+) channels by the selective serotonin-norepinephrine reuptake inhibitors duloxetine and venlafaxine. Stoetzer C; Papenberg B; Doll T; Völker M; Heineke J; Stoetzer M; Wegner F; Leffler A Eur J Pharmacol; 2016 Jul; 783():1-10. PubMed ID: 27130441 [TBL] [Abstract][Full Text] [Related]
10. Steroidogenic disruptive effects of the serotonin-noradrenaline reuptake inhibitors duloxetine, venlafaxine and tramadol in the H295R cell assay and in a recombinant CYP17 assay. Islin J; Munkboel CH; Styrishave B Toxicol In Vitro; 2018 Mar; 47():63-71. PubMed ID: 29100959 [TBL] [Abstract][Full Text] [Related]
11. Risk of stress cardiomyopathy associated with selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors: a real-world pharmacovigilance analysis. Tan B; Chen L; Yan S; Pan H; Zhang J; Wei H Sci Rep; 2024 Jul; 14(1):15167. PubMed ID: 38956425 [TBL] [Abstract][Full Text] [Related]
12. Healthcare Costs and Medication Adherence Among Patients with Fibromyalgia: Combination Medication vs. Duloxetine, Milnacipran, Venlafaxine, and Pregabalin Initiators. Marlow NM; Simpson KN; Vaughn IA; Jo A; Zoller JS; Short EB Pain Pract; 2018 Feb; 18(2):154-169. PubMed ID: 28419725 [TBL] [Abstract][Full Text] [Related]
13. Influence of Different Antidepressants on Ocular Surface in Patients With Major Depressive Disorder. Işik-Ulusoy S; Ulusoy MO J Clin Psychopharmacol; 2021 Jan/Feb 01; 41(1):49-52. PubMed ID: 33347023 [TBL] [Abstract][Full Text] [Related]
14. Hepatic effects of duloxetine-II: spontaneous reports and epidemiology of hepatic events. Wernicke J; Acharya N; Strombom I; Gahimer JL; D'Souza DN; DiPietro N; Uetrecht JP Curr Drug Saf; 2008 May; 3(2):143-53. PubMed ID: 18690992 [TBL] [Abstract][Full Text] [Related]
15. Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study. Huybrechts KF; Bateman BT; Pawar A; Bessette LG; Mogun H; Levin R; Li H; Motsko S; Scantamburlo Fernandes MF; Upadhyaya HP; Hernandez-Diaz S BMJ; 2020 Feb; 368():m237. PubMed ID: 32075794 [TBL] [Abstract][Full Text] [Related]
16. Duloxetine versus other anti-depressive agents for depression. Cipriani A; Koesters M; Furukawa TA; Nosè M; Purgato M; Omori IM; Trespidi C; Barbui C Cochrane Database Syst Rev; 2012 Oct; 10(10):CD006533. PubMed ID: 23076926 [TBL] [Abstract][Full Text] [Related]
17. Association of Antidepressant Medications With Incident Type 2 Diabetes Among Medicaid-Insured Youths. Burcu M; Zito JM; Safer DJ; Magder LS; dosReis S; Shaya FT; Rosenthal GL JAMA Pediatr; 2017 Dec; 171(12):1200-1207. PubMed ID: 29049533 [TBL] [Abstract][Full Text] [Related]
19. Serotonin-norepinephrine reuptake inhibitor and selective serotonin reuptake inhibitor use and risk of fractures: a new-user cohort study among US adults aged 50 years and older. Lanteigne A; Sheu YH; Stürmer T; Pate V; Azrael D; Swanson SA; Miller M CNS Drugs; 2015 Mar; 29(3):245-52. PubMed ID: 25708711 [TBL] [Abstract][Full Text] [Related]
20. Cerebrovascular, Cardiovascular, and Mortality Events in New Users of Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors: A Propensity Score-Matched Population-Based Study. Leong C; Alessi-Severini S; Enns MW; Nie Y; Sareen J; Bolton J; Prior HJ; Chateau D J Clin Psychopharmacol; 2017 Jun; 37(3):332-340. PubMed ID: 28383363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]